Baidu
map

AACR 2015:长期规律服用阿司匹林降低结直肠癌患病风险

2015-04-21 Zhang JL译 MedSci原创

根据在2015年4月18到22日的AACR年会的研究指出,长期规律服用阿司匹林与结直肠癌整体风险的降低相关。“过去关于阿司匹林与癌症关系的研究在规模大小、随访时间长度或服用阿司匹林与其他的生活方式因素影响方面受到限制。我们的研究提供了关于服用阿司匹林的潜在好处的重要信息,在一个人口众多的群体中研究一系列的剂量、时间和持续使用的时间在其中的影响。”波士顿哈佛公共卫生学院南加利福尼亚长期营养学系的研究

根据在2015年4月18到22日的AACR年会的研究指出,长期规律服用阿司匹林与结直肠癌整体风险的降低相关。

“过去关于阿司匹林与癌症关系的研究在规模大小、随访时间长度或服用阿司匹林与其他的生活方式因素影响方面受到限制。我们的研究提供了关于服用阿司匹林的潜在好处的重要信息,在一个人口众多的群体中研究一系列的剂量、时间和持续使用的时间在其中的影响。”波士顿哈佛公共卫生学院南加利福尼亚长期营养学系的研究员Yin Cao博士说。

在这个前瞻性研究中,Cao和他的同事们收集了82600名女性和47651名男性在服用阿司匹林、癌症诊断和其他风险因素的相关数据。经过32年的随访,27985个癌症事件被记录。

研究结果显示,每周服用两片或两片以上阿司匹林药片的患者整体癌症患病风险降低了15%。这种风险减少主要为胃肠道癌症减少20%所形成,包括结直肠癌减少25%和胃食管癌减少14%。

长期规律服用阿司匹林以及阿司匹林剂量的增加能够减少患癌症的风险。显著的风险降低只有在连续服用阿司匹林16年后才能体现,并且如在四年内停止服用则不再明显。研究人员发现,规律服用阿司匹林和非胃肠道癌症风险的减少无关,特别是乳腺癌、肺癌、前列腺癌。

该项研究作者、马萨诸塞州综合医院胃肠病学主任及哈佛医学院医学系副教授Andrew T. Chan博士,在4月20日(周一)上午8点45分为与会人员展示题为“分子阿司匹林化学预防的风险分层”的演讲。他说:“阿斯匹林已被证明是在预防心脏病和中风方面是有效的,尤其是那些之前有心血管事件历史的患者。然而,最近的研究表明,这些好处在心脏病或中风低患病风险的人群中则未如理想中明显。因此,我们的研究结果表明,对于许多个体来说阿司匹林预防癌症的潜在好处实际上可能大于预防心血管事件。通过进一步研究定义子集的人群可能获得定期服用阿司匹林获益的更有效证据。作为这一战略的一个例子,我们最近发现,个体的遗传背景可能会影响使用阿斯匹林降低结直肠癌风险的有效性。”

Cao告诫说:“尽管这些研究结果建议及早使用阿司匹林预防癌症,但个人需要与医生协商,并必须考虑到服用阿司匹林的潜在风险,包括肠胃道出血,”Cao博士说,“在推荐阿司匹林对癌症的化学预防之前,通过正在进行的研究将基于个体化来评估风险和收益,以开发出有针对性的治疗方案才至关重要。”

原始出处:

AACR Annual Meeting 2015 News:Long-term, Regular Aspirin Use Modestly Decreased Cancer Risk

本文系Medsci原创编译整理!转载需要先获得授权,并附原文链接。谢谢!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1281728, encodeId=2a291281e287a, content=<a href='/topic/show?id=ef315299070' target=_blank style='color:#2F92EE;'>#患病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52990, encryptionId=ef315299070, topicName=患病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Apr 23 12:20:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400319, encodeId=487a1400319dc, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Thu Apr 23 12:20:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452746, encodeId=2d1b1452e463b, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu Apr 23 12:20:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551959, encodeId=9c001551959e8, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Thu Apr 23 12:20:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21686, encodeId=51712168671, content=十分敬佩!致敬研究者!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=121e1622385, createdName=chenhui888, createdTime=Wed Apr 22 16:27:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21673, encodeId=596a216e317, content=这是迄今为止规模最大、历时最长的关于阿司匹林的研究了,持续十多年定期服用阿司匹林,可以保护人体避免一些胃肠道癌症,尤其是结直肠癌。, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150602/IMG556D2C119C3EC8067.jpg, createdBy=e2ea89702, createdName=gongzuozhong, createdTime=Wed Apr 22 14:13:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21640, encodeId=835621640fe, content=阿司匹林这么灵?, beContent=null, objectType=article, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dcd1622180, createdName=ZChWei, createdTime=Tue Apr 21 23:09:00 CST 2015, time=2015-04-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1281728, encodeId=2a291281e287a, content=<a href='/topic/show?id=ef315299070' target=_blank style='color:#2F92EE;'>#患病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52990, encryptionId=ef315299070, topicName=患病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Apr 23 12:20:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400319, encodeId=487a1400319dc, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Thu Apr 23 12:20:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452746, encodeId=2d1b1452e463b, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu Apr 23 12:20:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551959, encodeId=9c001551959e8, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Thu Apr 23 12:20:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21686, encodeId=51712168671, content=十分敬佩!致敬研究者!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=121e1622385, createdName=chenhui888, createdTime=Wed Apr 22 16:27:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21673, encodeId=596a216e317, content=这是迄今为止规模最大、历时最长的关于阿司匹林的研究了,持续十多年定期服用阿司匹林,可以保护人体避免一些胃肠道癌症,尤其是结直肠癌。, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150602/IMG556D2C119C3EC8067.jpg, createdBy=e2ea89702, createdName=gongzuozhong, createdTime=Wed Apr 22 14:13:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21640, encodeId=835621640fe, content=阿司匹林这么灵?, beContent=null, objectType=article, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dcd1622180, createdName=ZChWei, createdTime=Tue Apr 21 23:09:00 CST 2015, time=2015-04-21, status=1, ipAttribution=)]
    2015-04-23 10518094zz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1281728, encodeId=2a291281e287a, content=<a href='/topic/show?id=ef315299070' target=_blank style='color:#2F92EE;'>#患病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52990, encryptionId=ef315299070, topicName=患病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Apr 23 12:20:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400319, encodeId=487a1400319dc, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Thu Apr 23 12:20:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452746, encodeId=2d1b1452e463b, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu Apr 23 12:20:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551959, encodeId=9c001551959e8, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Thu Apr 23 12:20:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21686, encodeId=51712168671, content=十分敬佩!致敬研究者!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=121e1622385, createdName=chenhui888, createdTime=Wed Apr 22 16:27:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21673, encodeId=596a216e317, content=这是迄今为止规模最大、历时最长的关于阿司匹林的研究了,持续十多年定期服用阿司匹林,可以保护人体避免一些胃肠道癌症,尤其是结直肠癌。, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150602/IMG556D2C119C3EC8067.jpg, createdBy=e2ea89702, createdName=gongzuozhong, createdTime=Wed Apr 22 14:13:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21640, encodeId=835621640fe, content=阿司匹林这么灵?, beContent=null, objectType=article, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dcd1622180, createdName=ZChWei, createdTime=Tue Apr 21 23:09:00 CST 2015, time=2015-04-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1281728, encodeId=2a291281e287a, content=<a href='/topic/show?id=ef315299070' target=_blank style='color:#2F92EE;'>#患病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52990, encryptionId=ef315299070, topicName=患病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Apr 23 12:20:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400319, encodeId=487a1400319dc, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Thu Apr 23 12:20:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452746, encodeId=2d1b1452e463b, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu Apr 23 12:20:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551959, encodeId=9c001551959e8, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Thu Apr 23 12:20:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21686, encodeId=51712168671, content=十分敬佩!致敬研究者!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=121e1622385, createdName=chenhui888, createdTime=Wed Apr 22 16:27:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21673, encodeId=596a216e317, content=这是迄今为止规模最大、历时最长的关于阿司匹林的研究了,持续十多年定期服用阿司匹林,可以保护人体避免一些胃肠道癌症,尤其是结直肠癌。, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150602/IMG556D2C119C3EC8067.jpg, createdBy=e2ea89702, createdName=gongzuozhong, createdTime=Wed Apr 22 14:13:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21640, encodeId=835621640fe, content=阿司匹林这么灵?, beContent=null, objectType=article, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dcd1622180, createdName=ZChWei, createdTime=Tue Apr 21 23:09:00 CST 2015, time=2015-04-21, status=1, ipAttribution=)]
    2015-04-23 Luyuxie_14
  5. [GetPortalCommentsPageByObjectIdResponse(id=1281728, encodeId=2a291281e287a, content=<a href='/topic/show?id=ef315299070' target=_blank style='color:#2F92EE;'>#患病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52990, encryptionId=ef315299070, topicName=患病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Apr 23 12:20:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400319, encodeId=487a1400319dc, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Thu Apr 23 12:20:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452746, encodeId=2d1b1452e463b, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu Apr 23 12:20:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551959, encodeId=9c001551959e8, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Thu Apr 23 12:20:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21686, encodeId=51712168671, content=十分敬佩!致敬研究者!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=121e1622385, createdName=chenhui888, createdTime=Wed Apr 22 16:27:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21673, encodeId=596a216e317, content=这是迄今为止规模最大、历时最长的关于阿司匹林的研究了,持续十多年定期服用阿司匹林,可以保护人体避免一些胃肠道癌症,尤其是结直肠癌。, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150602/IMG556D2C119C3EC8067.jpg, createdBy=e2ea89702, createdName=gongzuozhong, createdTime=Wed Apr 22 14:13:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21640, encodeId=835621640fe, content=阿司匹林这么灵?, beContent=null, objectType=article, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dcd1622180, createdName=ZChWei, createdTime=Tue Apr 21 23:09:00 CST 2015, time=2015-04-21, status=1, ipAttribution=)]
    2015-04-22 chenhui888

    十分敬佩!致敬研究者!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1281728, encodeId=2a291281e287a, content=<a href='/topic/show?id=ef315299070' target=_blank style='color:#2F92EE;'>#患病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52990, encryptionId=ef315299070, topicName=患病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Apr 23 12:20:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400319, encodeId=487a1400319dc, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Thu Apr 23 12:20:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452746, encodeId=2d1b1452e463b, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu Apr 23 12:20:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551959, encodeId=9c001551959e8, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Thu Apr 23 12:20:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21686, encodeId=51712168671, content=十分敬佩!致敬研究者!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=121e1622385, createdName=chenhui888, createdTime=Wed Apr 22 16:27:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21673, encodeId=596a216e317, content=这是迄今为止规模最大、历时最长的关于阿司匹林的研究了,持续十多年定期服用阿司匹林,可以保护人体避免一些胃肠道癌症,尤其是结直肠癌。, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150602/IMG556D2C119C3EC8067.jpg, createdBy=e2ea89702, createdName=gongzuozhong, createdTime=Wed Apr 22 14:13:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21640, encodeId=835621640fe, content=阿司匹林这么灵?, beContent=null, objectType=article, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dcd1622180, createdName=ZChWei, createdTime=Tue Apr 21 23:09:00 CST 2015, time=2015-04-21, status=1, ipAttribution=)]
    2015-04-22 gongzuozhong

    这是迄今为止规模最大、历时最长的关于阿司匹林的研究了,持续十多年定期服用阿司匹林,可以保护人体避免一些胃肠道癌症,尤其是结直肠癌。

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1281728, encodeId=2a291281e287a, content=<a href='/topic/show?id=ef315299070' target=_blank style='color:#2F92EE;'>#患病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52990, encryptionId=ef315299070, topicName=患病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Apr 23 12:20:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400319, encodeId=487a1400319dc, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Thu Apr 23 12:20:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452746, encodeId=2d1b1452e463b, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu Apr 23 12:20:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551959, encodeId=9c001551959e8, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Thu Apr 23 12:20:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21686, encodeId=51712168671, content=十分敬佩!致敬研究者!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=121e1622385, createdName=chenhui888, createdTime=Wed Apr 22 16:27:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21673, encodeId=596a216e317, content=这是迄今为止规模最大、历时最长的关于阿司匹林的研究了,持续十多年定期服用阿司匹林,可以保护人体避免一些胃肠道癌症,尤其是结直肠癌。, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150602/IMG556D2C119C3EC8067.jpg, createdBy=e2ea89702, createdName=gongzuozhong, createdTime=Wed Apr 22 14:13:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21640, encodeId=835621640fe, content=阿司匹林这么灵?, beContent=null, objectType=article, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dcd1622180, createdName=ZChWei, createdTime=Tue Apr 21 23:09:00 CST 2015, time=2015-04-21, status=1, ipAttribution=)]
    2015-04-21 ZChWei

    阿司匹林这么灵?

    0

相关资讯

AACR 2014:I-SPY 2临床试验设计特色与要点

美国癌症研究协会年会(AACR)上发表的II期I-SPY 2研究的结果,其显示与标准化疗联合曲妥珠单抗方案相比,化疗联合neratinib联合治疗HER-2阳性、受体阴性的乳腺癌患者的完全缓解率更高。I-SPY 2研究纳入了高危、II期/III期的乳腺癌患者。详细见报道:AACR 2014:乳腺癌新药neratinib疗效优于曲妥珠单抗(I-SPY 2研究) 实际上,这个研究的设计也相当具有特色。

AACR 2015现场报道:美国癌症研究会年会肿瘤免疫治疗重点

今天是美国癌症研究会2015年年会第一天,会议安排了4场关于肿瘤免疫治疗的大型的学术活动。内容主要包括以下几个方面:一、围绕检测点阻断治疗探讨进一步提高疗效的方法,寻找能够预测检测点治疗疗效的生物学标志物,以及探索为什么这一疗法在一些肿瘤当中疗效不好的原因比如结肠癌;二、介绍了肿瘤治疗性疫苗研究的最新进展以及提高疗效的策略;三、针对对免疫功能具有抑制作用的肿瘤微环境的治疗策略,主要涉及三个方面;I

AACR2013:他汀类药物可显著降低乳腺癌死亡率

一项大型数据库研究显示,在乳腺癌诊断前后使用他汀类药物可使乳腺癌死亡风险降低66%。在美国癌症研究协会(AACR)2013年会上该研究的作者Teemu Murtola医生报道说即使在控制年龄、肿瘤分期、以及形态学特征和初治方案等因素后发现风险减少的趋势依然不变。 约翰霍普金斯大学的流行病学家Teemu J. Murtola医生及其同事指出,“在他汀类药物使用者人群中,我们观察到乳腺癌死亡风险存在

AACR 2014:肺癌新药MK-3475作用与肿瘤中PD-L1蛋白浓度有关

应用正在研究中的免疫检测点抑制剂MK-3475治疗的非小细胞肺癌患者中,那些肿瘤中PD-L1蛋白浓度较高的患者的预后更好,该I期临床研究结果报告在2014年4月5-9日举行的AACR年会上。该试验的初始数据报道于今年的早些时候,数据显示MK-3475治疗的耐受性较好,可以使以前治疗过的非小细胞肺癌患者达到持久而客观的缓解,尤其是那些在治疗前PD-L1的浓度就很高的肿瘤的患者。最近的结果扩展了这些数

AACR 2015现场报道:美国癌症研究会年会热门方向概述

开幕式以后,接着有六个大会演讲,分别代表了目前肿瘤研究中五个热门方向:肿瘤突变过程和mutation signiture(基因组学),基因工程研究,表观遗传组学研究,基因组学与肿瘤个体化免疫治疗,PD-1单抗pembrolizumab的临床III期临床研究结果(肿瘤免疫治疗),和靶向治疗。默沙东公司今天在大会上首次介绍了pembrolizumab在黑色素瘤中的三期临床结果:与ipilimumab相

Baidu
map
Baidu
map
Baidu
map